

Menha Swellam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5795916/publications.pdf>

Version: 2024-02-01

55
papers

938
citations

430442

18
h-index

500791

28
g-index

58
all docs

58
docs citations

58
times ranked

1313
citing authors

#	ARTICLE	IF	CITATIONS
1	Noninvasive Diagnosis of Bladder Cancer by Detection of Matrix Metalloproteinases (MMP-2 and Tj ETQq1 1 0.784314 rgBT /Overloc	0.9	89
2	Comparative Evaluation of the Nuclear Matrix Protein, Fibronectin, Urinary Bladder Cancer Antigen and Voided Urine Cytology in the Detection of Bladder Tumors. Journal of Urology, 2002, 168, 465-469.	0.2	50
3	Detection of Telomerase in Urine by 3 Methods: Evaluation of Diagnostic Accuracy for Bladder Cancer. Journal of Urology, 2007, 178, 1068-1072.	0.2	45
4	Expression of HYAL1 and Survivin RNA as Diagnostic Molecular Markers for Bladder Cancer. Journal of Urology, 2010, 183, 493-498.	0.2	42
5	Aberrant Methylation of <i>RARβ2</i> and <i>APC</i> Genes in Voided Urine as Molecular Markers for Early Detection of Bilharzial and Nonbilharzial Bladder Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1657-1664.	1.1	42
6	Comparison of CD44 and cytokeratin 20 mRNA in voided urine samples as diagnostic tools for bladder cancer. Clinical Biochemistry, 2008, 41, 1335-1341.	0.8	37
7	Aberrant methylation of <i>APC</i> and <i>RARβ2</i> genes in breast cancer patients. IUBMB Life, 2015, 67, 61-68.	1.5	35
8	Potential diagnostic role of circulating MiRNAs in breast cancer: Implications on clinicopathological characters. Clinical Biochemistry, 2018, 56, 47-54.	0.8	34
9	Clinical impact of circulating oncogenic MiRNA-221 and MiRNA-222 in glioblastoma multiform. Journal of Neuro-Oncology, 2019, 144, 545-551.	1.4	34
10	Association of nonalcoholic fatty liver disease with a single nucleotide polymorphism on the gene encoding leptin receptor. IUBMB Life, 2012, 64, 180-186.	1.5	32
11	miRNA-155 and miRNA-181a as prognostic biomarkers for pediatric acute lymphoblastic leukemia. Journal of Cellular Biochemistry, 2019, 120, 6315-6321.	1.2	30
12	Clinical impact of circulating microRNAs as blood-based marker in childhood acute lymphoblastic leukemia. Tumor Biology, 2016, 37, 10571-10576.	0.8	25
13	Clinical significance of blood-based miRNAs as diagnostic and prognostic nucleic acid markers in breast cancer: Comparative to conventional tumor markers. Journal of Cellular Biochemistry, 2019, 120, 12321-12330.	1.2	24
14	A Panel of Angiogenic Factors for Early Bladder Cancer Detection: Enzyme Immunoassay and Western Blot. Journal of Urology, 2009, 181, 1353-1360.	0.2	22
15	Metronomic chemotherapy in metastatic breast cancer: Impact on VEGF. Journal of the Egyptian National Cancer Institute, 2012, 24, 15-22.	0.6	22
16	Role of some circulating MiRNAs on breast cancer diagnosis. Archives of Physiology and Biochemistry, 2019, 125, 456-464.	1.0	21
17	The clinical relevance of urine-based markers for diagnosis of bladder cancer. Medical Oncology, 2011, 28, 513-518.	1.2	20
18	Aberrant Expression of Some Circulating miRNAs in Childhood Acute Lymphoblastic Leukemia. Biochemical Genetics, 2018, 56, 283-294.	0.8	20

#	ARTICLE	IF	CITATIONS
19	Comparison of cytokeratin 20 RNA and angiogenin in voided urine samples as diagnostic tools for bladder carcinoma. <i>Clinical Biochemistry</i> , 2004, 37, 803-810.	0.8	18
20	Emerging Role of P53, Bcl-2 and Telomerase Activity in Egyptian Breast Cancer Patients. <i>IUBMB Life</i> , 2004, 56, 483-490.	1.5	16
21	Clinical Implications of Adiponectin and Inflammatory Biomarkers in Type 2 Diabetes Mellitus. <i>Disease Markers</i> , 2009, 27, 269-278.	0.6	16
22	Clinical aspects of circulating miRNA-335 in breast cancer patients: A prospective study. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 8975-8982.	1.2	16
23	Serum MiRNA-27a as potential diagnostic nucleic marker for breast cancer. <i>Archives of Physiology and Biochemistry</i> , 2021, 127, 90-96.	1.0	16
24	Impact of circulating miRNA-373 on breast cancer diagnosis through targeting VEGF and cyclin D1 genes. <i>Journal of Genetic Engineering and Biotechnology</i> , 2021, 19, 84.	1.5	16
25	Diagnosis of hepatitis C virus infection by enzyme-linked immunosorbent assay and reverse transcriptase-nested polymerase chain reaction: A comparative evaluation. <i>IUBMB Life</i> , 2011, 63, 430-434.	1.5	15
26	Clinical impact of LncRNA XIST and LncRNA NEAT1 for diagnosis of high-risk group breast cancer patients. <i>Current Problems in Cancer</i> , 2021, 45, 100709.	1.0	14
27	Emerging Role of Endothelial and Inflammatory Markers in Preeclampsia. <i>Disease Markers</i> , 2009, 26, 127-133.	0.6	13
28	Emerging role of miRNAs as liquid biopsy markers for prediction of glioblastoma multiforme prognosis. <i>Journal of Molecular Neuroscience</i> , 2021, 71, 836-844.	1.1	13
29	Incidence of Bcl-2 expression in bladder cancer: relation to schistosomiasis. <i>Clinical Biochemistry</i> , 2004, 37, 798-802.	0.8	12
30	Prognostic value of cell-cycle regulators and cellular biomarkers in laryngeal squamous cell carcinoma. <i>Clinical Biochemistry</i> , 2008, 41, 1059-1066.	0.8	12
31	Soluble cytokeratin-19 and E-selectin biomarkers: Their relevance for lung cancer detection when tested independently or in combinations. <i>Cancer Biomarkers</i> , 2008, 4, 43-54.	0.8	12
32	Clinical role of MiRNA 29a and MiRNA 335 on breast cancer management: their relevance to MMP2 protein level. <i>Archives of Physiology and Biochemistry</i> , 2022, 128, 1058-1065.	1.0	12
33	Diagnostic value of urinary molecular markers in bladder cancer. <i>Anticancer Research</i> , 2003, 23, 4347-55.	0.5	12
34	Deletions of p15 and p16 in schistosomal bladder cancer correlate with transforming growth factor- β expression. <i>Clinical Biochemistry</i> , 2004, 37, 1098-1104.	0.8	10
35	Interleukin-1 receptor antagonist gene polymorphism and hepcidin in rheumatoid arthritis: Correlations with clinical and laboratory indices of disease activity. <i>IUBMB Life</i> , 2013, 65, 883-888.	1.5	9
36	Clinical impact of PTEN methylation status as a prognostic marker for breast cancer. <i>Journal of Genetic Engineering and Biotechnology</i> , 2021, 19, 66.	1.5	9

#	ARTICLE	IF	CITATIONS
37	Potential Influence of Interleukin-1 Receptor Antagonist Gene Polymorphism on Knee Osteoarthritis Risk. <i>Disease Markers</i> , 2010, 28, 299-305.	0.6	8
38	Apolipoprotein E genotyping in Egyptian diabetic nephropathy patients. <i>IUBMB Life</i> , 2016, 68, 58-64.	1.5	8
39	Clinical implications of adiponectin and inflammatory biomarkers in type 2 diabetes mellitus. <i>Disease Markers</i> , 2009, 27, 269-78.	0.6	8
40	Alterations of PTEN and SMAD4 methylation in diagnosis of breast cancer: implications of methyl II PCR assay. <i>Journal of Genetic Engineering and Biotechnology</i> , 2021, 19, 54.	1.5	7
41	Anti-mullerian and androgens hormones in women with polycystic ovary syndrome undergoing IVF/ICSI. <i>Iranian Journal of Reproductive Medicine</i> , 2013, 11, 883-90.	0.8	6
42	Prognostic utility of lncRNAs (LINC00565 and LINC00641) as molecular markers in glioblastoma multiforme (GBM). <i>Journal of Neuro-Oncology</i> , 0, , .	1.4	6
43	Clinical implications of HER-2/neu overexpression and proteolytic activity imbalance in breast cancer. <i>IUBMB Life</i> , 2007, 59, 394-401.	1.5	5
44	Expression of MiR-335 and its target metalloproteinase genes: clinical significance in breast cancer. <i>Archives of Physiology and Biochemistry</i> , 2022, 128, 569-575.	1.0	5
45	Relevance of circulating MiRNA-21 and MiRNA-181 in prediction of glioblastoma multiforme prognosis. <i>Archives of Physiology and Biochemistry</i> , 2020, , 1-6.	1.0	5
46	Emerging role of endothelial and inflammatory markers in preeclampsia. <i>Disease Markers</i> , 2009, 26, 127-33.	0.6	4
47	Next generation sequencing of <i>BRCA</i> genes in glioblastoma multiform Egyptian patients: a pilot study. <i>Archives of Physiology and Biochemistry</i> , 2022, 128, 809-817.	1.0	3
48	Diagnostic Role of Aberrant DNA Promoter Methylation in Ovarian Cancer. <i>Annual Research & Review in Biology</i> , 2017, 19, 1-13.	0.4	3
49	Clinical implications of proteolytic activity imbalance in breast cancer diagnosis. <i>Cancer Biomarkers</i> , 2014, 14, 409-417.	0.8	2
50	Potential influence of interleukin-1 receptor antagonist gene polymorphism on knee osteoarthritis risk. <i>Disease Markers</i> , 2010, 28, 299-305.	0.6	2
51	Assessment of maintenance oral etoposide following induction chemotherapy with gemcitabine and cisplatin in chemo-naïve extensive small cell lung cancer. <i>Chinese-German Journal of Clinical Oncology</i> , 2010, 9, 569-573.	0.1	1
52	Skeletal events of Anastrozole versus Tamoxifen on bone mineral density and bone biomarker osteocalcin in postmenopausal women with early breast cancer. <i>Chinese-German Journal of Clinical Oncology</i> , 2010, 9, 574-578.	0.1	0
53	Evaluation of Osteopontin and Pok α mon genes expression in hepatitis C virus-associated hepatocellular carcinoma. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 7439-7445.	1.2	0
54	Implications of targeted next-generation sequencing for bladder cancer: report of four cases. <i>Journal of Genetic Engineering and Biotechnology</i> , 2021, 19, 91.	1.5	0

#	ARTICLE	IF	CITATIONS
55	Clinical Impact of Oncomirs 221 and 222 on Breast Cancer Diagnosis. Asia-Pacific Journal of Oncology, 2020, , 1-9.	0.2	0